BenevolentAI, a leading AI-powered biopharma company, announced today that Dr. Joerg Moeller, a veteran in the pharmaceutical industry, has joined the company as its new CEO and Executive Board member.

Dr. Joerg Moeller has over 20 years of experience in leading global R&D organisations and driving innovation and value creation. He has also been involved in several AI-based drug discovery collaborations and strategic partnerships. He previously served as EVP and Head of R&D at LEO Pharma and Bayer Pharmaceuticals.

Dr. Joerg Moeller will lead BenevolentAI’s vision to accelerate the discovery and development of new medicines using its advanced AI platform. He will be based in London and work with Dr. François Nader, the Independent Non-Executive Chair of the company.

Dr. François Nader, Chair of BenevolentAI, commented: “Along with the rest of the Board, I am delighted to welcome Joerg. Joerg is an outstanding leader with extensive experience across all stages of R&D. He is a strong advocate of AI as a driver of discovery innovation and effectiveness. With his track record of delivering growth through driving performance, I am confident that Joerg will leverage our proprietary and validated Benevolent Platform™ to deliver our patient-centric revenue generating strategy.”

Dr. Joerg Moeller, Chief Executive Officer of BenevolentAI, commented: “I am excited by the opportunity to lead BenevolentAI. I believe the Company is well-positioned to further capitalise on its Platform, pipeline and research capabilities in order to strengthen the Company’s market position and continue to build its commercial activities. I am passionate about fostering a culture of excellence, innovation, and diversity and I look forward to working with the Board, the Leadership Team and BenevolentAI employees to create value for all its stakeholders ultimately helping to deliver treatments to the patients who need them.”

BenevolentAI announces strategic plan to boost AI and biopharma businesses